School of Pharmacy, Queen's University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast BT9 7BL, UK.
J Mater Chem B. 2024 May 8;12(18):4375-4388. doi: 10.1039/d4tb00110a.
Hydrogel-forming microneedles (HF-MNs) are composed of unique cross-linked polymers that are devoid of the active pharmaceutical ingredient (API) within the microneedle array. Instead, the API is housed in a reservoir affixed on the top of the baseplate of the HF-MNs. To date, various types of drug-reservoirs and multiple solubility-enhancing approaches have been employed to deliver hydrophobic molecules combined with HF-MNs. These strategies are not without drawbacks, as they require multiple manufacturing steps, from solubility enhancement to reservoir production. However, this current study challenges this trend and focuses on the delivery of the hydrophobic antibiotic rifampicin using SmartFilm-technology as a solubility-enhancing strategy. In contrast to previous techniques, smart drug-reservoirs (SmartReservoirs) for hydrophobic compounds can be manufactured using a one step process. In this study, HF-MNs and three different concentrations of rifampicin SmartFilms (SFs) were produced. Following this, both HF-MNs and SFs were fully characterised regarding their physicochemical and mechanical properties, morphology, Raman surface mapping, the interaction with the cellulose matrix and maintenance of the loaded drug in the amorphous form. In addition, their drug loading and transdermal permeation efficacy were studied. The resulting SFs showed that the API was intact inside the cellulose matrix within the SFs, with the majority of the drug in the amorphous state. SFs alone demonstrated no transdermal penetration and less than 20 ± 4 μg of rifampicin deposited in the skin layers. In contrast, the transdermal permeation profile using SFs combined with HF-MNs (. SmartReservoirs) demonstrated a 4-fold increase in rifampicin deposition (80 ± 7 μg) in the skin layers and a permeation of approx. 500 ± 22 μg. Results therefore illustrate that SFs can be viewed as novel drug-reservoirs ( SmartReservoirs) for HF-MNs, achieving highly efficient loading and diffusion properties through the hydrogel matrix.
水凝胶形成的微针 (HF-MN) 由独特的交联聚合物组成,这些聚合物中不含有微针阵列中的活性药物成分 (API)。相反,API 被储存在固定在 HF-MN 基片顶部的储库中。迄今为止,已经使用了各种类型的药物储库和多种增溶方法来递送与 HF-MN 结合的疏水分子。这些策略并非没有缺点,因为它们需要从增溶到储库生产的多个制造步骤。然而,本研究挑战了这一趋势,专注于使用 SmartFilm 技术作为增溶策略来递送疏水性抗生素利福平。与以前的技术不同,疏水性化合物的智能储库 (SmartReservoirs) 可以通过一步法制造。在本研究中,生产了 HF-MN 和三种不同浓度的利福平 SmartFilm (SF)。随后,对 HF-MN 和 SF 进行了全面的理化和机械性能、形貌、拉曼表面映射、与纤维素基质的相互作用以及载药保持无定形状态的特性研究。此外,还研究了它们的药物负载和透皮渗透效果。结果表明,SF 中的 API 完整地存在于 SF 中的纤维素基质中,大部分药物处于无定形状态。SF 本身没有透皮渗透,只有不到 20 ± 4μg 的利福平沉积在皮肤层中。相比之下,使用 SF 结合 HF-MN (.SmartReservoirs)的透皮渗透谱显示,利福平的沉积量增加了 4 倍(80 ± 7μg),皮肤层中的渗透量约为 500 ± 22μg。结果表明,SF 可以被视为 HF-MN 的新型药物储库(SmartReservoirs),通过水凝胶基质实现高效的负载和扩散性能。